# Sanderling Ventures

> Sanderling Ventures is a VC fund backing Biotechnology and Health Care. See 59 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Mateo, United States
- Total investments: 59
- Last investment: Apr 2025
- Lead investor: 22%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/sanderling-ventures/
- Website: http://www.sanderling.com
- Facebook: https://www.facebook.com/pg/Sanderling-Ventures

Sanderling Ventures is an investment company that specializes in seed and early-stage investments. It also participates in later-stage financings. The firm focuses on new biomedical market opportunities, including emerging technology in the areas such as biotechnology, life sciences, therapeutics and pharmaceuticals, drug delivery, medical devices,and instrumentation; imaging and diagnostics, medical informatics, healthcare information technology; and health care services. It seeks to invest in United States and Canada.Sanderling Ventures was founded by Robert McNeil in 1979 and is headquartered in Sam Mateo, California.

## Contacts

5 contacts available for Sanderling Ventures. Shizune tracks 8 team members at Sanderling Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/sanderling-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 24 | 41% |
| Health Care | 23 | 39% |
| Medical | 10 | 17% |
| Pharmaceutical | 8 | 14% |
| Therapeutics | 7 | 12% |

18 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 14 | 24% |
| Series C | 12 | 20% |
| Series A | 8 | 14% |
| Series D | 7 | 12% |
| Funding Round | 7 | 12% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 25 | 42% |
| Canada | 4 | 7% |
| India | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Fred Middleton | Managing Director | 8 | https://shizune.co/investors/profile/fred-middleton |
| Timothy C. Mills | Managing Director | 9 | https://shizune.co/investors/profile/timothy-c-mills |
| Timothy Wollaeger | Managing Director | 11 | https://shizune.co/investors/profile/timothy-wollaeger |
| Michael Dixon | Managing Director | 0 | https://shizune.co/investors/profile/michael-dixon-6 |
| Paulette Taylor | General Counsel & Principal | 0 | https://shizune.co/investors/profile/paulette-taylor |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Glycomine | Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options. | $115M | Series C | Apr 16, 2025 |  |
| CalciMedica | CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $55M | Post-IPO Equity | Jan 22, 2024 |  |
| Glycomine | Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options. | $35M | Series B | Jun 23, 2021 |  |
| ViaCyte | ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeuticallyrelevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications. |  | Series D | Apr 22, 2021 |  |
| CalciMedica | CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $21M | Series D | Mar 11, 2021 |  |
| CalciMedica | CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $15M | Series C | May 22, 2020 |  |
| ViaCyte | ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeuticallyrelevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications. | $32.6M | Series D | Mar 20, 2020 |  |
| Glycomine | Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options. | $33M | Series B | Aug 07, 2019 |  |
| Metavention | Metavention develops medical devices to help with interventional therapies for Type 2 diabetes. | $65M | Series C | Jan 08, 2018 |  |
| SpecificiT Pharma | SpecificiT Pharma Inc., a privately held biopharmaceutical company focused on developing innovative personalized cancer immunotherapies.SpecificiT is developing cellular therapies for hematological cancers which to date, cannot be treated with chimeric antigen receptor modified T cells (CAR-T) therapies.SpecificiT’s unique approach iscentered on the use of Minor Histocompatability Antigens (“MiHAs”) which enable donor T-cells to be safely directed to eliminate cancer cells in a patient. |  | Seed | Sep 11, 2017 |  |

10 of 59 investments shown.

## Co-investors
- [Mayo Clinic Ventures](https://shizune.co/investors/profile/mayo-clinic-ventures) — VC Fund, 6 deals together
- [Intel Capital](https://shizune.co/investors/profile/intel-capital) — VC Fund, 4 deals together
- [PrairieGold Venture Partners](https://shizune.co/investors/profile/prairiegold-venture-partners) — VC Fund, 4 deals together
- [Qualcomm Ventures](https://shizune.co/investors/profile/qualcomm-ventures) — VC Fund, 4 deals together
- [Bain Capital Life Sciences](https://shizune.co/investors/profile/bain-capital-life-sciences) — VC Fund, 3 deals together
- [Chiesi Ventures](https://shizune.co/investors/profile/chiesi-ventures) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Titan Capital](https://shizune.co/investors/profile/titan-capital) — VC Fund
- [Inflection Point Ventures](https://shizune.co/investors/profile/inflection-point-ventures-d275) — VC Fund
- [Blume Ventures](https://shizune.co/investors/profile/blume-ventures) — VC Fund

## Featured in investor lists
- [Biotechnology VC Funds in India](https://shizune.co/investors/biotechnology-vc-funds-india)
- [Biotech VC Funds in India](https://shizune.co/investors/biotech-vc-funds-india)
- [Biotechnology Investors in India](https://shizune.co/investors/biotechnology-investors-india)
- [Biotech Investors in India](https://shizune.co/investors/biotech-investors-india)

## FAQ

### What does Sanderling Ventures invest in?

Sanderling Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 59 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Sanderling Ventures?

Public channels for Sanderling Ventures include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Sanderling Ventures?

The team at Sanderling Ventures includes Fred Middleton (Managing Director), Timothy C. Mills (Managing Director) and Timothy Wollaeger (Managing Director), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co